Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Retinoid X receptor-a (RXRA; RXRa); tumor necrosis factor-a (TNF-a)

Cell culture studies suggest a xanthone called CF31, isolated from the Cratoxylum formosum plant, could be useful for treating cancer. An in vitro screen identified CF31 as an inhibitor of truncated RXRa. In human cancer cell lines, CF31 induced apoptosis via a TNF-a-dependent pathway. Next steps could include studies to optimize CF31's anticancer effect and evaluate the compound in additional preclinical models.

SciBX 5(48); doi:10.1038/scibx.2012.1254
Published online Dec. 13, 2012

Compound patented; available for licensing

Zhang, X.-k. et al. Cancer Res.; published online Nov. 14, 2012;
doi:10.1158/0008-5472.CAN-12-2038
Contact: Xiao-kun Zhang, Sanford-Burnham Medical Research Institute, La Jolla, Calif.
e-mail:
xzhang@sanfordburnham.org